GDNF neurons produce and release glial cell line-derived neurotrophic factor (GDNF), a potent neurotrophic factor that belongs to the GDNF family of ligands (GFL). Unlike other neurotrophins such as BDNF, GDNF exhibits remarkable specificity for dopaminergic neurons and motor neurons, making it a leading candidate for treating Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS)[1][2].
GDNF was originally discovered in 1973 as a factor promoting the survival of cultured dopaminergic neurons, and its identification led to extensive research into its therapeutic potential. The GDNF family includes several related proteins—GDNF, neurturin (NRTN), artemin (ARTN), persephin (PSPN), and neublastin (NBN)—each signaling through a specific receptor complex consisting of a GFRα (GDNF family receptor alpha) family member and the RET (rearranged during transfection) receptor tyrosine kinase[3].
The human GDNF gene (GDNF) is located on chromosome 5p13.1 and encodes a 211-amino acid precursor protein that undergoes proteolytic processing to generate the mature, biologically active GDNF (approximately 14 kDa)[1:1]. The mature GDNF protein is a disulfide-linked homodimer that functions as the active form.
GDNF exhibits several unique biochemical properties:
GDNF signaling is mediated through a bipartite receptor system:
GFRα1 (GDNF family receptor alpha 1):
RET (Rearranged during transfection):
Alternative receptors:
GDNF activates multiple intracellular signaling cascades:
Cell survival pathways:
Neurite outgrowth:
Synaptic function:
GDNF-expressing neurons are distributed throughout the brain and spinal cord:
Substantia nigra pars compacta (SNc):
Striatum:
Spinal cord:
GDNF has been extensively studied as a potential treatment for Parkinson's disease due to its specific trophic effects on dopaminergic neurons[5]:
Preclinical evidence:
Clinical trials:
Challenges and limitations:
GDNF protects motor neurons and has been investigated for ALS treatment[12]:
Mechanisms:
Therapeutic approaches:
Clinical status:
Stroke:
Peripheral neuropathy:
Huntington's disease:
Direct infusion:
Challenges:
Viral vectors:
Non-viral delivery:
Neural stem cells:
Immortalized cell lines:
Age-related changes in GDNF expression may contribute to neurodegeneration:
Reduced expression:
Therapeutic implications:
GDNF interacts with neuroinflammatory processes:
Anti-inflammatory effects:
Glial interactions:
GDNF exhibits significant anti-inflammatory effects:
Microglial modulation: GDNF reduces pro-inflammatory cytokine production from activated microglia, including TNF-α, IL-1β, and IL-6. This creates a neuroprotective feedback loop where GDNF both protects neurons and limits harmful inflammation.
Astrocyte interactions: Astrocytes both produce and respond to GDNF, forming bidirectional communication that modulates neuroinflammation. GDNF-treated astrocytes adopt more neuroprotective phenotypes.
T cell regulation: Emerging evidence suggests GDNF modulates adaptive immune responses in the CNS, potentially reducing autoimmune-mediated damage.
Neuroinflammation impairs GDNF signaling:
Receptor downregulation: Chronic inflammation reduces GFRα1 and RET expression on neurons, limiting their responsiveness to GDNF.
Signal transduction disruption: Inflammatory pathways interfere with GDNF-mediated PI3K/Akt and MAPK/ERK signaling.
Transport impairment: Inflammation disrupts GDNF transport along axons, reducing delivery to target regions.
GDNF has been extensively studied as a potential treatment for Parkinson's disease due to its specific trophic effects on dopaminergic neurons[5:2]:
Preclinical evidence:
Clinical trials:
Challenges and limitations:
Mechanism of neuroprotection:
GDNF protects motor neurons and has been investigated for ALS treatment[12:1]:
Mechanisms:
Therapeutic approaches:
Clinical status:
GDNF shows potential in Alzheimer's disease models:
Neuroprotective effects:
Combination approaches: GDNF with other trophic factors may provide synergistic benefits.
GDNF may protect striatal neurons in HD:
The prototype member of the family:
The GFRα family consists of four members:
GFRα1: Primary receptor for GDNF
GFRα2: Primary receptor for neurturin
GFRα3: Primary receptor for artemin
GFRα4: Primary receptor for persephin
GDNF activates PI3K through RET:
Pro-survival signaling:
Autophagy regulation: GDNF prevents excessive autophagy through Akt-mediated inhibition.
ERK activation mediates:
Neurite outgrowth: Through phosphorylation of microtubule-associated proteins
Gene expression: Through transcription factor activation including ELK-1
Differentiation: Promotes transition from proliferative to differentiated state
Phospholipase C activation:
Calcium mobilization: IP3-mediated calcium release from ER stores
DAG signaling: Activates PKC isoforms
Gene regulation: Calcium-dependent transcription factors
GDNF expression patterns during development:
Embryonic: High expression in the developing CNS, particularly in regions where neurons are generated and differentiate.
Postnatal: Decreases in most brain regions but remains important in specific areas like the substantia nigra and spinal cord.
Adult: Lower basal expression but can be upregulated in response to injury.
During development, GDNF:
Specific developmental windows when GDNF is essential:
Dopaminergic development: During the period of dopaminergic neuron survival (E14-P14 in mice)
Motor neuron development: Critical period for spinal motor neuron survival
Enteric nervous system: GDNF essential for gut innervation during embryogenesis
GDNF as a biomarker:
CSF levels: Can be measured in cerebrospinal fluid
Peripheral markers: Blood and urine measurements under development
Correlation with disease: Altered levels in PD, AD, and other neurodegenerative conditions
GDNF levels may predict:
Next-generation GDNF therapeutics:
Improved stability: Modified versions with extended half-life
Enhanced penetration: Variants designed to cross the blood-brain barrier
Selectivity: Engineered ligands with improved receptor specificity
GDNF with other interventions:
With exercise: Synergistic effects on dopaminergic neuron survival
With medications: Enhanced delivery through pharmacological manipulation
With cell therapy: Combined cellular and protein-based approaches
Personalized approaches:
Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. GDNF: a glial cell line-derived neurotrophic factor. Science. 1993. ↩︎ ↩︎
Airaksinen MS, Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nature Reviews Neuroscience. 2002. ↩︎
Saarma M, Sariola H. Glial cell line-derived neurotrophic factor and its receptor. Annals of Medicine. 2000. ↩︎
Keller GA, Granda B, Tatti KM, Fong M, Narayana H, Vitek MP, et al. GDNF content in the brain of aged rats: Evidence for region-specific alterations. Neurobiology of Aging. 2011. ↩︎
Gash DM, Zhang Z, Ovadia A, Cass WA, Yi A, Simerman S, et al. Functional recovery in parkinsonian monkeys treated with GDNF. Nature. 1996. ↩︎ ↩︎ ↩︎ ↩︎
Tomac A, Lindqvist E, Lin LF, Ogren SO, Young D, Hoffer BJ, et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature. 1995. ↩︎ ↩︎
Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L, et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science. 2000. ↩︎ ↩︎ ↩︎
Gill SS, Patel NK, Hotton GR, O'Sullivan K, McCarter R, Bunnage M, et al. Direct brain infusion of GDNF in Parkinson disease. Nature Medicine. 2003. ↩︎ ↩︎
Lang AE, Gill S, Patel N, Lozano A, Nutt J, Penn R, et al. Randomized controlled trial of intraputamenal GDNF infusion for advanced Parkinson's disease. Annals of Neurology. 2006. ↩︎ ↩︎
Ramachandran B, Kumar A. AAV-mediated gene therapy for neurodegenerative diseases. Molecular Therapy. 2021. ↩︎ ↩︎ ↩︎
Henderson MX, Wijesekera O, Liguori M, O'Sullivan SS, Lee J, Volpicelli-Daley L, et al. GDNF does not provide trophic support to mutant α-synuclein overexpressing neurons. Neurobiology of Disease. 2020. ↩︎ ↩︎
Rao M, Lowery M, Vande Velde C, Patel D, Yung D, Chen Z, et al. Neural stem cell-based therapies for ALS. Annals of Neurology. 2006. ↩︎ ↩︎
Sandhu JK, Pandey S, Vijayapandi V, Deranie J, Srivastava R, Pandey D, et al. GDNF and neurotrophic factor delivery for neuroprotection in stroke. Translational Stroke Research. 2020. ↩︎
Barneoud P, Prechter T, Klockgether T, Lahlou S, Feger J, Mazдри J, et al. Neurturin accelerates the onset of motor deficits in a rat model of PD. Brain Research. 2000. ↩︎ ↩︎
Kumar A, Koprich J, Typlt K, Brodski M, Hutter J, Kott M, et al. Neurturin-based gene therapy for Parkinson's disease. Brain Research. 2020. ↩︎ ↩︎
Pfasth C, Scholer A, Schreppel C, Eggert M, Lorenzen J, Steiner J, et al. Long-term delivery of GDNF via AAV vectors. Human Gene Therapy. 2020. ↩︎
Liu Z, Chen Y, Tao R, Wang W, Jiang T, Su W, et al. GDNF-modified neural stem cells for Parkinson's disease treatment. Journal of Cellular and Molecular Medicine. 2019. ↩︎